KVUE Kenvue Inc: Company Value to Revenue Ratio

Public company logo of Kenvue Inc (KVUE)

The stability of the external environment and the neutral status of its products ensure sustainable growth for Kenvue Inc. (KVUE), as confirmed by the company's current price-to-sales ratio on GURU.Markets. The value of 2858.47 reflects the metric's balance, drawing on years of trust in the quality of pharmacy brands. The business foundation is built on the daily habits of families who have integrated iconic care products into their routines.

Kenvue Corp (KVUE) - Company Value to Revenue from 11/23/2025 to 11/14/2026

Financial and market metric breakdowns for Kenvue Corp (KVUE)

- price and consensus price forecast:
Fundamental company valuation:KVUE (kenvue.com)
Core merchandise of Kenvue Inc

For Kenvue Inc. (KVUE), the historical EV/Sales level serves as a tool for assessing the market value of the business relative to sales volumes, excluding the impact of leverage. This metric compares the total enterprise value to revenue, allowing for the identification of fundamental overvaluation or undervaluation of the asset during periods of market volatility. For a company with a high proportion of outsourced production and logistics, this indicator is critical, as it reflects the efficiency of brand monetization while minimizing capital expenditures.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Verona Pharma (VRNA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Jyong Biotech Limited (MENS)|LGND (Ligand Pharmaceuticals Incorporated) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amneal Pharmaceuticals Inc AMRX|EV/Sales Multiple PRGO|Enterprise Value-to-Revenue Coefficient ALVO|EV/Sales Multiple LQDA (Liquidia Technologies)|EV/Sales Multiple Galapagos GLPG|ANI Pharmaceuticals Inc - EV/Sales Multiple|MNKD (MannKind Corp.) - Company Value to Revenue Ratio|AMPH: EV/Sales Multiple|PCRX (Pacira BioSciences) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio